Drugs / VB-201
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04939311 | Jul 2022 → Jul 2026 | HIV infectious disease, cardiovascular disorder | Priscilla Hsue, MD | Withdrawn | No outcome recorded Stop: Business |
| Phase 25 trials | ||||||
| Phase 2 | NCT04733833 | Jan 2021 → Oct 2022 | COVID-19 | Vascular Biogenics Ltd. operating as VBL Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01839214 | Jan 2013 → Nov 2014 | ulcerative colitis | Vascular Biogenics Ltd. operating as VBL Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01837420 | Nov 2012 → Nov 2014 | psoriasis | Vascular Biogenics Ltd. operating as VBL Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01159730 | Oct 2010 → Oct 2011 | — | Vascular Biogenics Ltd. operating as VBL Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01001468 | Dec 2009 → Jul 2011 | psoriasis | Vascular Biogenics Ltd. operating as VBL Therapeutics | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VB-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01159730 ↗ |
| Action | Inhibit | “Monocyte differentiation antigen CD14 inhibitor” CHEMBL4297333 ↗1“Toll-like receptor 2 inhibitor” CHEMBL4297333 ↗ |
| Modality | Small molecule | — CHEMBL4297333 ↗ |
| Route | Oral | “Single daily dose of oral VB-201 20 mg” NCT01001468 ↗ |
| Target | CD14 | “Monocyte differentiation antigen CD14 inhibitor” CHEMBL4297333 ↗ |
| Target | TLR2 | “Toll-like receptor 2 inhibitor” CHEMBL4297333 ↗ |